StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Zetia (ezetimibe, legacy pre-Organon spin-off) by Year

Zetia (ezetimibe, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M)

QuarterlyAnnual

Merck Zetia (ezetimibe, legacy pre-Organon spin-off): $482M in FY2020, down 18.3% from a year earlier. No newer figure appears in the documents we track.

Latest, FY2020
482
Period ended Dec 31, 2020
Change on a year earlier
-18.3%
590 in FY2019
History
5 years
Since FY2016
Sources
5
Documents cited below

Where the FY2020 figure comes from

“|| Zetia | 92 | 145 | 137 | 103 | 98 | 482 | -37 | -41”

Source: Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedZetia (ezetimibe, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M)Year on yearSource
FY2020Dec 31, 2020482-18.3%Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
FY2019Dec 31, 2019590-31.2%Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
FY2018Dec 31, 2018857-36.2%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
FY2017Dec 31, 20171,344-47.5%Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
FY2016Dec 31, 20162,560–Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗

Breakdown

What makes up zetia (ezetimibe, legacy pre-Organon spin-off)

Cite this data

StockData. (2026). Merck Zetia (ezetimibe, legacy pre-Organon spin-off) ($M), annual FY2016–FY2020 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-zetia

See every metric in the Merck KPI table. Data updated Oct 26, 2026.